IHS Chemical Week

People & Business :: M&A

Bayer bids to acquire Norwegian pharma company Algeta

1:29 PM MST | November 26, 2013 | Natasha Alperowicz

The board of directors of Algeta (Oslo) today announced that it has received a preliminary acquisition proposal from Bayer. Bayer has offered to pay 336 Norwegian Krone per Algeta share, valuing the bid at $2.4 billion. Algeta is Bayer’s partner in a new prostate cancer treatment. Algeta says discussions are at an early stage and further announcements may be made in due course.   Bayer and Algeta are partners in Xofigo, which was approved by the US FDA on 15 May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa